Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells $51,830.80 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 1,730 shares of the stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $29.96, for a total value of $51,830.80. Following the transaction, the chief financial officer now owns 86,370 shares of the company’s stock, valued at approximately $2,587,645.20. This trade represents a 1.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Wednesday, January 22nd, Timothy Eugene Sullivan sold 3,088 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $30.43, for a total transaction of $93,967.84.
• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total transaction of $62,279.00.

Apellis Pharmaceuticals Stock Performance

APLS opened at $30.76 on Friday. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The business’s 50 day moving average is $31.95 and its 200-day moving average is $33.25. The stock has a market cap of $3.83 billion, a PE ratio of -15.15 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. During the same period in the previous year, the firm earned ($1.17) EPS. The firm’s revenue was up 78.3% on a year-over-year basis. On average, analysts predict that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wolverine Asset Management LLC bought a new position in Apellis Pharmaceuticals in the 3rd quarter valued at about $27,000. True Wealth Design LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter worth approximately $27,000. Capital Performance Advisors LLP acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter worth approximately $56,000. KBC Group NV boosted its holdings in shares of Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after acquiring an additional 679 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Apellis Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after acquiring an additional 781 shares during the period. 96.29% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on APLS. HC Wainwright restated a “buy” rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday, January 14th. Bank of America reduced their target price on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Needham & Company LLC lowered their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. William Blair began coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set an “outperform” rating on the stock. Finally, Mizuho lowered their target price on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, October 24th. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).